Physician profile
David J Brown
NPI 1861433195
$3,813.54
in general payments reported to CMS, 2019-2025
35 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $253 · 2021: $901 · 2022: $807 · 2023: $517 · 2024: $485 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,100.35 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $452.65 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $451.70 | 2019-2023 | |
| Novo Nordisk INC | $267.47 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $130.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $119.24 | 2021-2024 | Eliquis |
| Astellas Pharma US INC | $114.03 | 2019-2022 | |
| Glaxosmithkline, LLC. | $105.27 | 2021-2024 | Arexvy, Shingrix |
| Medtronic, INC. | $101.93 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $94.48 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $90.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.25 | 2019-2022 | |
| Eisai INC. | $73.44 | 2021-2025 | |
| Lilly USA, LLC | $70.92 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Allergan, INC. | $66.18 | 2020 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.